专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20210077565A1 NUCLEOTIDE AND CELLULAR VACCINE COMPOSITION 有权
公开(公告)号：US20210077565A1
公开(公告)日：2021-03-18
申请号：US16985393
申请日：2020-08-05
申请人： Mallen HUANG
发明人： Mallen HUANG
IPC分类号： A61K38/08 , A61K39/00
摘要： A method of treating a Philadelphia chromosome-positive tumor in a subject comprises administering to the subject a therapeutic composition comprising an incubated combined mixture of (a) a first component comprising (i) Philadelphia chromosome-positive tumor lysate, (ii) plasmid encoding bcr/abl fusion protein, or (iii) bcr/abl fusion peptide; and (b) a second component comprising plasmacytoid dendritic cells expressing Toll-like receptor 9 and modified for stable expression of CD40 ligand or GM-CSF by a nucleotide sequence engineered into said plasmacytoid dendritic cells.

2. 发明授权

US10799553B2 Composition comprising a nucleotide sequence encoding an ELA2 fusion protein and plasmacytoid dendritic cells 有权
公开(公告)号：US10799553B2
公开(公告)日：2020-10-13
申请号：US10551804
申请日：2004-04-14
申请人： Mallen Huang
发明人： Mallen Huang
IPC分类号： A61K39/00 , A61K38/08
摘要： The present invention refers to a novel combination of nucleotide and cellular vaccine composition and pharmaceutical composition and use thereof for treating and/or preventing diseases, including infectious diseases, cancer, autoimmune diseases, allergy, diabetes and blood disorders. The vaccine composition comprises a nucleotide sequence encoding an antigenic molecule and gene-modified antigen-presenting cells (APCs), preferably provided as an intermixture. The APCs are modified to express immune modulating molecules. Immunization with the vaccine composition of present invention into a subject, induces the host immune system to respond and generate efficient immunity against either pre-existing disease or protect the host against the disease.

3. 发明申请

US20070071722A1 Nucleotide vaccine composition 审中-公开
标题翻译：核苷酸疫苗组合物
公开(公告)号：US20070071722A1
公开(公告)日：2007-03-29
申请号：US10551804
申请日：2004-04-14
申请人： Mallen Huang
发明人： Mallen Huang
IPC分类号： A61K48/00 , A61K38/19
摘要： The present invention refers to a novel combination of nucleotide and cellular vaccine composition and pharmaceutical composition and use thereof for treating and/or preventing diseases, including infectious diseases, cancer, autoimmune diseases, allergy, diabetes and blood disorders. The vaccine composition comprises a nucleotide sequence encoding an antigenic molecule and gene-modified antigen-presenting cells (APCs), preferably provided as an intermixture. The APCs are modified to express immune modulating molecules. Immunization with the vaccine composition of present invention into a subject, induces the host immune system to respond and generate efficient immunity against either pre-existing disease or protect the host against the disease.
摘要翻译：本发明涉及核苷酸和细胞疫苗组合物和药物组合物及其用于治疗和/或预防疾病，包括感染性疾病，癌症，自身免疫性疾病，变态反应，糖尿病和血液病症的新型组合。疫苗组合物包含编码抗原分子和基因修饰的抗原呈递细胞（APC）的核苷酸序列，优选作为混合物提供。 APCs被修饰以表达免疫调节分子。将本发明的疫苗组合物免疫接种到受试者中，诱导宿主免疫系统响应并产生针对预先存在的疾病或保护宿主免受疾病的有效免疫。

4. 发明授权

US11298398B2 Method of treating a philadelphia chromosome-positive tumor 有权
公开(公告)号：US11298398B2
公开(公告)日：2022-04-12
申请号：US16985393
申请日：2020-08-05
申请人： Mallen Huang
发明人： Mallen Huang
IPC分类号： A61K38/08 , A61K39/00
摘要： A method of treating a Philadelphia chromosome-positive tumor in a subject comprises administering to the subject a therapeutic composition comprising an incubated combined mixture of (a) a first component comprising (i) Philadelphia chromosome-positive tumor lysate, (ii) plasmid encoding bcr/abl fusion protein, or (iii) bcr/abl fusion peptide; and (b) a second component comprising plasmacytoid dendritic cells expressing Toll-like receptor 9 and modified for stable expression of CD40 ligand or GM-CSF by a nucleotide sequence engineered into said plasmacytoid dendritic cells.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式